Skip to main content
. 2014 Feb;3(1):53–63. doi: 10.3978/j.issn.2218-6751.2014.01.01

Table 2. Summary of completed and ongoing immunotherapy trials in small cell lung cancer.

Immunotherapy Target Phase Stage Results
BEC2/BCG GD3 III Limited stage SCLC OS 16.4 months with BSC and 14.3 months with BEC2/BCG; HR =1.12; 95% CI: 0.91-1.371 (55)
Ipilimumab or placebo + paclitaxel/carboplatin CTLA-4 II Previously untreated extensive stage SCLC Phased Ipilimumab improved irPFS vs. control (HR: 0.64; P=0.03) (56)
Ipilimumab/carboplatin/etoposide CTLA-4 II Previously untreated extensive stage SCLC Ongoing (57)
Carboplatin/etoposide +/– ipilimumab CTLA-4 III Previously untreated extensive stage SCLC Ongoing (58)
Nivolumab +/– ipilimumab PD1 and CTLA-4 II Previously treated after first line extensive stage SCLC Ongoing (59)

BSC, best supportive care; HR, hazard ratio; OR, overall response.